Protocol LV-101-3-01: Phase 3, Randomized, Double-Blind, Placebo-Controlled, 8-week Clinical Study to Assess the Efficacy, Safety, and Tolerability of Intranasal Carbetocin (LV-101) in Prader-Willi Syndrome Patients (PWS) with Long-Term Follow-Up

Project: Research project

Project Details

StatusActive
Effective start/end date1/30/19 → 8/31/50

Funding

  • Levo Therapeutics, Inc.